Figure 1
From: Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis

Comparison of survival probability according to treatment modality in GAP stage I (a) and GAP ((gender [G], age [A]), and two physiology variables (P) (FVC and DLCO)) stage system) stage II and III (b). Cox regression models were adjusted for lung cancer clinical stages, Eastern Cooperative Oncology Group (ECOG), primary treatment, and total amount of cigarettes smoked in a lifetime.